Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with intermediate and advanced/relapsed hepatocellular carcinoma: a TOS-ESMO initiative endorsed by CSCO, ISMPO, JSMO, KSMO, MOS and SSO
Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with intermediate and advanced/relapsed hepatocellular carcinoma: a TOS-ESMO initiative endorsed by CSCO, ISMPO, JSMO, KSMO, MOS and SSO
复制标题
DOI：
10.1016/j.annonc.2019.12.001
复制
发表时间：
2020-03-01
影响因子：
50.5
通讯作者：
Douillard, J-Y
中科院分区：
文献类型：
--
作者：
Chen, L-T;Martinelli, E.;Douillard, J-Y
最新版本的欧洲医学肿瘤学会(ESMO)肝细胞癌(HCC)诊断、治疗和随访临床实践指南于2018年发布，涵盖了早、中、晚期疾病的诊断、管理、治疗和后续行动。在2018年11月的ESMO亚洲会议上，ESMO和台湾肿瘤学会(TOS)决定在2019年5月在台北举行的台湾癌症联合会议(TJCC)之后立即召开一次特别指南会议。其目的是调整ESMO 2018年指南，以考虑到与亚洲患者肝癌治疗相关的实践中的种族和地理差异。这些指南代表了台湾肿瘤学会、中国肿瘤学会、印度肿瘤学会、日本肿瘤学会、韩国肿瘤学会、马来西亚肿瘤学会和新加坡肿瘤学会在治疗中级和晚期/复发肝癌患者方面达成的共识意见。投票是以科学证据为基础的，与目前的治疗做法、药物供应情况和个别参与国的报销情况无关。
The most recent version of the European Society for Medical Oncology (ESMO) Clinical Practice Guidelines for the diagnosis, treatment and follow-up of hepatocellular carcinoma (HCC) was published in 2018, and covered the diagnosis, management, treatment and follow-up of early, intermediate and advanced disease. At the ESMO Asia Meeting in November 2018 it was decided by both the ESMO and the Taiwan Oncology Society (TOS) to convene a special guidelines meeting immediately after the Taiwan Joint Cancer Conference (TJCC) in May 2019 in Taipei. The aim was to adapt the ESMO 2018 guidelines to take into account both the ethnic and the geographic differences in practice associated with the treatment of HCC in Asian patients. These guidelines represent the consensus opinions reached by experts in the treatment of patients with intermediate and advanced/relapsed HCC representing the oncology societies of Taiwan (TOS), China (CSCO), India (ISMPO) Japan (JSMO), Korea (KSMO), Malaysia (MOS) and Singapore (SSO). The voting was based on scientific evidence, and was independent of the current treatment practices, the drug availability and reimbursement situations in the individual participating Asian countries.